FDA Approves Akeega for BRCA-Positive Metastatic Prostate Cancer
THURSDAY, Aug. 17, 2023 -- The U.S. Food & Drug Administration has approved Akeega (niraparib and abiraterone acetate) for the treatment of BRCA-positive metastatic castration-resistant prostate cancer. The approval makes Akeega the first and...